Portage Biotech Inc. (NASDAQ:PRTG) Short Interest Update

Portage Biotech Inc. (NASDAQ:PRTG) was the recipient of a significant growth in short interest in the month of February. As of February 28th, there was short interest totalling 17,400 shares, a growth of 33.8% from the February 13th total of 13,000 shares. Approximately 10.6% of the company’s shares are short sold. Based on an average daily trading volume, of 650,300 shares, the short-interest ratio is presently 0.0 days.

Portage Biotech Trading Up 1.2 %

NASDAQ:PRTG traded up $0.05 during mid-day trading on Tuesday, hitting $4.30. The company had a trading volume of 3,221 shares, compared to its average volume of 641,543. The business has a fifty day simple moving average of $4.42 and a 200-day simple moving average of $4.95. The firm has a market capitalization of $4.51 million, a price-to-earnings ratio of -0.10 and a beta of 1.29. Portage Biotech has a 1 year low of $2.10 and a 1 year high of $23.01.

Institutional Investors Weigh In On Portage Biotech

A hedge fund recently bought a new stake in Portage Biotech stock. Virtu Financial LLC purchased a new stake in Portage Biotech Inc. (NASDAQ:PRTG) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 10,919 shares of the company’s stock, valued at approximately $73,000. Virtu Financial LLC owned about 1.04% of Portage Biotech as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 13.36% of the company’s stock.

Portage Biotech Company Profile

Portage Biotech Inc, a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials.